ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Articles By Drug Pricing

Cost-effectiveness Threshold and Health Opportunity Cost

With the setting up of the health technology assessment board, evidence from cost-effectiveness analysis will play an important role in decision-making. This raises the fundamental question: How much extra cost per unit of health gained is considered cost-effective? Various approaches for assessing the appropriate cost-effectiveness threshold for India are discussed. A robustly determined opportunity cost of healthcare spending should serve as a proxy for setting up a CET, and it should be used to advocate for greater resources towards achieving universal health coverage.

Thrombolytic Treatment for Myocardial Infarction

All authors were formerly at Council of Scientific and Industrial Research HQ, New Delhi. This study looks at the available life-saving treatments for heart attacks and ischaemic heart diseases administered in India, focusing on streptokinase and finding that it is the life-saving clot-buster for the majority of patients. This brings to light that the surgical intervention of angioplasty is more of an income-biased treatment. Public-funded research and development of indigenous streptokinase has directly enabled access to treatment, especially for economically challenged patients.